A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
Inclusion Criteria:
Exclusion Criteria:
Cheonan-si, Chungcheongnam-do 31181, South Korea
Changwon-si,, Gyeongsangnam-do 51595, South Korea
Changwon-si, Gyeongsangnam-do 51449, South Korea
Changwon-si, Gyeongsangnam-do 51472, South Korea
Hwasun-gun, Jeollanam-do 58128, South Korea
Mokpo-si, Jeollanam-do 58640, South Korea
Mokpo-si, Jeollanam-do 58664, South Korea
Mokpo-si, Jeollanam-do 58707, South Korea